Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
100 Clinical Results associated with AXL x FGFRs x MerTK x PDGFRs x VEGFR2 x VEGFR3 x c-Kit
100 Translational Medicine associated with AXL x FGFRs x MerTK x PDGFRs x VEGFR2 x VEGFR3 x c-Kit
0 Patents (Medical) associated with AXL x FGFRs x MerTK x PDGFRs x VEGFR2 x VEGFR3 x c-Kit